Transcriptomics

Dataset Information

0

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients


ABSTRACT: In preclinical experiments, cyclic fasting-mimicking diets (FMDs) showed broad anticancer effects in combination with chemotherapy. Among different tumor types, triple-negative breast cancer (TNBC) is exquisitely sensitive to FMD. However, the antitumor activity and efficacy of cyclic FMD in TNBC patients remain unclear. Here, we show that a severely calorie-restricted, triweekly, 5-day FMD regimen results in excellent pathologic complete response (pCR) rates (primary endpoint) and long-term clinical outcomes (secondary endpoints) when combined with preoperative chemotherapy in 30 patients with early-stage TNBC enrolled in the phase II trial BREAKFAST. Bulk and single-cell RNA-sequencing analysis revealed that highly glycolytic cancer cells, myeloid cells and pericytes from tumors achieving pCR undergo a significant, early downmodulation of pathways related to glycolysis and pyruvate metabolism. Our findings pave the wave for conducting larger clinical trials to investigate the efficacy of cyclic FMD in early-stage TNBC patients, and to validate early changes of intratumor glycolysis as a predictor of clinical benefit from nutrient restriction. ClinicalTrials.gov Identifier: NCT04248998

ORGANISM(S): Homo sapiens

PROVIDER: GSE279219 | GEO | 2024/10/15

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-01-26 | GSE184452 | GEO
2024-10-23 | GSE279842 | GEO
| EGAS00001004944 | EGA
2021-08-19 | GSE163060 | GEO
2020-05-27 | PXD015141 | Pride
2024-08-05 | GSE272653 | GEO
2013-01-15 | E-GEOD-43502 | biostudies-arrayexpress
2023-08-14 | GSE212911 | GEO
2024-04-26 | GSE243865 | GEO
2013-01-15 | GSE43502 | GEO